DK2806883T3 - Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation - Google Patents

Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation Download PDF

Info

Publication number
DK2806883T3
DK2806883T3 DK13706770.8T DK13706770T DK2806883T3 DK 2806883 T3 DK2806883 T3 DK 2806883T3 DK 13706770 T DK13706770 T DK 13706770T DK 2806883 T3 DK2806883 T3 DK 2806883T3
Authority
DK
Denmark
Prior art keywords
immunomodulation
biomarkers
combination therapies
oncolytic virus
oncolytic
Prior art date
Application number
DK13706770.8T
Other languages
English (en)
Inventor
Frank Tufaro
Juan Fueyo-Margareto
Frederick Lang
Candelaria Gomez-Manzano
W K Alfred Yung
Amy Heimberger
Charles Conrad
Original Assignee
Dnatrix Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnatrix Inc, Univ Texas filed Critical Dnatrix Inc
Application granted granted Critical
Publication of DK2806883T3 publication Critical patent/DK2806883T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
DK13706770.8T 2012-01-25 2013-01-25 Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation DK2806883T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590441P 2012-01-25 2012-01-25
US201261637191P 2012-04-23 2012-04-23
PCT/US2013/023304 WO2013112942A1 (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation

Publications (1)

Publication Number Publication Date
DK2806883T3 true DK2806883T3 (da) 2019-07-22

Family

ID=47754947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13706770.8T DK2806883T3 (da) 2012-01-25 2013-01-25 Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation

Country Status (11)

Country Link
US (3) US10238698B2 (da)
EP (2) EP3578198A1 (da)
JP (3) JP2015508156A (da)
KR (1) KR102081567B1 (da)
CN (1) CN104427992B (da)
AU (2) AU2013211871B2 (da)
BR (1) BR112014018331A8 (da)
CA (1) CA2862390A1 (da)
DK (1) DK2806883T3 (da)
SG (3) SG10201604654RA (da)
WO (1) WO2013112942A1 (da)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2013116778A2 (en) 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
WO2013131050A1 (en) * 2012-03-02 2013-09-06 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for differential treatment of cancer
WO2013169971A1 (en) * 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EA201590451A1 (ru) * 2012-08-30 2016-05-31 Эмджен Инк. Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
CN114317461A (zh) * 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
AU2015222685A1 (en) * 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
WO2015184061A2 (en) * 2014-05-28 2015-12-03 Dana-Farber Cancer Institute, Inc. Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
ES2841075T3 (es) * 2014-10-24 2021-07-07 Calidi Biotherapeutics Inc Enfoque de inmunoterapia de combinación para el tratamiento del cáncer
ES2883249T3 (es) * 2015-03-17 2021-12-07 Mayo Found Medical Education & Res Métodos y materiales para evaluar y tratar el cáncer
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3302541A4 (en) 2015-06-03 2018-12-05 Aelan Cell Technologies Inc. Methods and devices for the production and delivery of beneficial factors from stem cells
EP3217993A1 (en) 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
US10370647B2 (en) * 2015-07-22 2019-08-06 National University Corporation Tottori University Host regulatory factor that enhances replication and/or propagation of vaccinia virus
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
KR20180048804A (ko) 2015-09-04 2018-05-10 아슬란 파마슈티컬스 피티이 엘티디 바리티닙 및 항암제를 포함하는 병용 요법
WO2017062615A2 (en) * 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
WO2017066557A1 (en) * 2015-10-15 2017-04-20 Duke University Combination treatment
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
US11065332B2 (en) * 2015-11-04 2021-07-20 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
EP3400291B2 (en) 2016-01-08 2024-02-28 Replimune Limited Engineered virus
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
AU2017210224B2 (en) * 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
CN105603085B (zh) * 2016-01-29 2019-01-29 北京泱深生物信息技术有限公司 椎间盘退行性病变的诊治靶标
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
MA55153A (fr) * 2016-02-19 2021-09-29 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
US11497781B2 (en) * 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017176289A1 (en) * 2016-04-08 2017-10-12 Celgene Corporation Uses of lenalidomide and car t-cells
GB201608918D0 (en) * 2016-05-20 2016-07-06 Aslan Pharmaceuticals Pte Ltd Method
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
WO2017218757A1 (en) * 2016-06-17 2017-12-21 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
WO2018071824A1 (en) * 2016-10-13 2018-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
EP3534923A4 (en) 2016-11-01 2020-05-27 DNAtrix, Inc. COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018111902A1 (en) * 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP3568145B1 (en) * 2017-01-13 2025-06-11 Mayo Foundation for Medical Education and Research Materials and methods for treating cancer
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CN108338994A (zh) 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
WO2018148336A1 (en) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
WO2018152095A1 (en) * 2017-02-14 2018-08-23 Celgene Corporation Treatment of cancer with smg1-inhibitors
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
CA3087276A1 (en) * 2018-01-17 2019-07-25 Eli Lilly And Company Compounds and methods targeting interleukin-19
CN108414660B (zh) * 2018-03-08 2020-03-20 中国药科大学 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
KR102091567B1 (ko) * 2018-06-15 2020-03-20 인하대학교 산학협력단 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물
CN112601547A (zh) 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
CN110755619A (zh) * 2018-07-27 2020-02-07 复旦大学 一种人疱疹病毒裂解复制激活的宿主标志物及其用途
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN108998529A (zh) * 2018-08-30 2018-12-14 上海交通大学医学院附属上海儿童医学中心 肺腺癌检测试剂盒及检测tulp2基因甲基化水平的方法
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
SG11202110338XA (en) * 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
EP3946421A4 (en) * 2019-03-28 2022-12-21 Mayo Foundation for Medical Education and Research IFNBETA AS A PHARMACODYNAMIC MARKER OF ONCOLYTIC VSV IFNBETA NIS THERAPY
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
MA55911A (fr) 2019-05-08 2022-03-16 2Seventy Bio Inc Lymphocytes t génétiquement modifiés
EP3977136A4 (en) * 2019-05-24 2023-05-10 Edifice Health, Inc. PRECISION DRUGS FOR CANCER IMMUNOTHERAPY
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
CN110687281B (zh) * 2019-08-26 2023-05-23 中国医学科学院肿瘤医院 Pd-l1自身抗体在肿瘤预后评估中的应用
JP2022545191A (ja) * 2019-08-29 2022-10-26 バイオノックス インコーポレイテッド 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物
US20220381769A1 (en) * 2019-09-23 2022-12-01 Sillajen, Inc. Immune Assay for Monitoring Response to Oncolytic Vaccinia Virus and Uses Thereof
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
JP7730487B2 (ja) 2020-05-08 2025-08-28 ルニット インコーポレイテッド 免疫抗癌剤に対する反応を予測する方法及びシステム
KR102628046B1 (ko) * 2020-05-08 2024-01-23 주식회사 루닛 면역 항암제에 대한 반응을 예측하는 방법 및 시스템
JP7731556B2 (ja) 2020-05-08 2025-09-01 ルニット インコーポレイテッド 病理スライドイメージに対する免疫表現型と関連付けられた情報を提供する方法及び装置
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN111579788A (zh) * 2020-05-29 2020-08-25 郑州大学 一种高灵敏肿瘤标志物EPHA2的Simoa试剂盒及其应用
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
CN116322728B (zh) * 2020-08-14 2026-07-31 上海行深生物科技有限公司 水疱性口炎病毒及其治疗用途
CN112345755B (zh) * 2020-09-23 2023-06-16 杭州凯保罗生物科技有限公司 乳腺癌的生物标志物及其应用
KR102710867B1 (ko) * 2020-12-18 2024-09-27 (주)인비보텍 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
JP2024500575A (ja) * 2020-12-22 2024-01-09 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド がんの早期かつ正確な検出のための、血液ベースのタンパク質バイオマーカーパネル
CN114764101B (zh) * 2021-01-25 2025-08-08 武汉大学中南医院 一种确定具有gbm预后价值的血液炎症标志物的方法及gbm生存率计算系统
WO2023107878A1 (en) * 2021-12-06 2023-06-15 Oncorus, Inc. Compositions and methods of seneca valley virus (svv) related cancer therapy
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
CN115948557B (zh) * 2023-01-04 2025-09-02 陕西师范大学 一种nlrp2作为靶点在卵巢癌疾病诊断和/或治疗中的应用
CN120835927A (zh) * 2023-09-28 2025-10-24 复旦大学附属华山医院 用于治疗胶质瘤的组合物
WO2026097419A1 (zh) * 2024-11-08 2026-05-15 深圳市华药康明生物药业有限责任公司 溶瘤病毒治疗人群的筛选方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
FI972225L (fi) 1994-11-28 1997-07-16 Genetic Therapy Inc Vektorit kudosspesifistä replikaatiota varten
WO1996033280A1 (en) 1995-04-17 1996-10-24 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6080578A (en) 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
JP2002514075A (ja) 1997-03-03 2002-05-14 セル ジェネシス，インコーポレイティド 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
WO2000029599A1 (en) 1998-11-18 2000-05-25 Canji, Inc. Viral vectors with late transgene expression
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
EP1180932B1 (en) 1999-05-12 2012-01-11 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
DE60036105D1 (de) 1999-06-08 2007-10-04 Uab Research Foundation Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
AU1190901A (en) 1999-09-30 2001-04-30 Trustees Of The University Of Pennsylvania, The Replication selective adenoviruses for use in cancer therapy
EP1223947A4 (en) 1999-10-15 2004-12-08 Canji Inc TARGETED VECTORS
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
JP5522884B2 (ja) 2004-03-31 2014-06-18 具紀 藤堂 ウイルス療法の抗癌作用増強剤、癌の予防または治療方法
EP1773846A4 (en) 2004-07-13 2008-10-08 Univ British Columbia INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
EP1877090B1 (en) 2005-05-06 2014-01-15 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
KR101704734B1 (ko) * 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2825762A1 (en) 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Method for enhancing anti-neoplastic activity of an oncolytic virus using modified dendritic cells
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
EA201500417A1 (ru) * 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
BRPI0924123B8 (pt) * 2008-12-22 2021-05-25 Oncos Therapeutics Oy vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2407177A1 (en) 2010-07-13 2012-01-18 Institut Gustave Roussy Adenovirus vaccine vectors
EP2383577A1 (en) 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
WO2013116778A2 (en) 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
KR20160054456A (ko) 2013-06-18 2016-05-16 디엔에이트릭스, 인코포레이티드 종양용해성 아데노바이러스를 사용한 뇌암의 치료

Also Published As

Publication number Publication date
AU2018201776A1 (en) 2018-04-05
EP3578198A1 (en) 2019-12-11
CN104427992B (zh) 2017-12-19
WO2013112942A1 (en) 2013-08-01
JP2021103174A (ja) 2021-07-15
KR102081567B1 (ko) 2020-02-26
JP2019066482A (ja) 2019-04-25
US20190269744A1 (en) 2019-09-05
US20200330533A1 (en) 2020-10-22
CN104427992A (zh) 2015-03-18
JP2015508156A (ja) 2015-03-16
BR112014018331A8 (pt) 2017-07-11
KR20150008846A (ko) 2015-01-23
HK1204577A1 (en) 2015-11-27
US10238698B2 (en) 2019-03-26
SG11201404313YA (en) 2014-10-30
SG10201604654RA (en) 2016-07-28
BR112014018331A2 (da) 2017-06-20
EP2806883A1 (en) 2014-12-03
SG10201913784YA (en) 2020-03-30
EP2806883B1 (en) 2019-04-24
CA2862390A1 (en) 2013-08-01
HK1208349A1 (en) 2016-03-04
US11065285B2 (en) 2021-07-20
US20140377221A1 (en) 2014-12-25
AU2013211871A1 (en) 2014-08-14
AU2013211871B2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
SG10201913784YA (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
IL269045A (en) Aptamers and uses thereof
PT2922875T (pt) Anticorpos anti-ceacam5 e suas utilizações
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2855736T3 (da) Elektrolysator og energisystem
IL236838A0 (en) Antibodies against dengue virus and uses thereof
HRP20160862T1 (hr) Sklop posude i pridruženi postupak
DK2850202T3 (da) Fremgangsmåder og grupper
DK2877832T3 (da) System til mikrofluidisk orientering og sortering af partikler
IL228347A0 (en) Antibodies directed against icos and uses thereof
DK2838917T3 (da) Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
LT2699270T (lt) Adeno-asocijuoto viruso virionai su variantine kapside ir jų naudojimo būdai
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
EP2772078A4 (en) SYSTEMS AND METHODS FOR TWO-FACTOR AUTHENTICATION
EP2932192A4 (en) FREQUENZAUSLESEGYROSKOP
IL236874A0 (en) Anti-kit antibodies and uses thereof
DK2801139T3 (da) Fremgangsmåde og apparat til styring af frekvensomformer
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
DK2805670T3 (da) Forbedringer af og i sammenhæng med oftalmoskoper
CO6870031A2 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
PT2976084T (pt) Combinação compreendendo zidovudina e polimixina
DK2877576T3 (da) Xyloseisomeraser og anvendelser deraf
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf